Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: A review of the evidence

World Allergy Organization Journal

Volumn 4, Issue 2, 2011, Pages 47-53

  Canonica, Walter ^a   Blaiss, Michael ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Allergic rhinitis; Anti inflammatory; Antihistamine; Desloratadine; Second generation antihistamines; Urticaria

Indexed keywords

ANTIHISTAMINIC AGENT; CAREBASTINE; CETIRIZINE; CYCLIC AMP; DESLORATADINE; EBASTINE; FEXOFENADINE; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LEVOCETIRIZINE; LORATADINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MIZOLASTINE; RANTES; RUPATADINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ALLERGIC RHINITIS; ALLERGIC URTICARIA; ANTIINFLAMMATORY ACTIVITY; BASOPHIL; CELL ACTIVATION; CELL ADHESION; CELL MIGRATION; CELL SURVIVAL; CELL TYPE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EOSINOPHIL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 79954444911     PISSN: 19394551     EISSN: None     Source Type: Journal    
DOI: 10.1097/WOX.0b013e3182093e19     Document Type: Review

References (62)

1. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533:69 -76. (Pubitemid 43340005)
2. Akdis CA, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 2008;94:67- 82.
3. Schneider E, Rolli-Derkinderen M, Arock M, Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol. 2002;23:255-263. (Pubitemid 34499563)
4. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy. 2001;56:21-27. (Pubitemid 32156194)
5. Zuberbier T, Asero R, Bindslev-Jensen C. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1418 -1426.
6. 4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov. 2008;7:41-53.
7. 1 receptor itself through activation of receptor gene transcription. J Pharmacol Sci. 2007;103:374 -382. (Pubitemid 46640690)
8. 1 -antihistamines. N Engl J Med. 2004;351: 2203-2217.
9. 2LEN and Aller- Gen). Allergy. 2008;63(Suppl 86):8 -160. (Pubitemid 351357811)
10. 2LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64:1427-1443.
11. 1 antihistamines. J Investig Allergol Clin Immunol. 2006;16(Suppl 1):3-12. (Pubitemid 46057825)
12. 1 - receptor antagonist: desloratadine, the model paradigm. Clin Drug Invest. 2005;25:153-164. (Pubitemid 40460641)
13. 1 antihistamines: clinical relevance. Am J Med. 2002;113(Suppl 9A):38S-46S. (Pubitemid 36459495)
14. 2-receptor antagonists. Exp Dermatol. 2000;9:118 -124. (Pubitemid 30192709)
15. 1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489-498. (Pubitemid 34429565)
16. 2LEN study. Allergy. 2009;64:1516 -1523.
17. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123:672- 679.
18. 2LEN. Ann Allergy Asthma Immunol. 2009;102:A119.
19. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007;62:359 -366. (Pubitemid 46398792)
20. Ortonne J-P, Grob J-J, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol. 2007;8:37- 42. (Pubitemid 46998562)
21. Pradalier A, Neukirch C, Dreyfus I, Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy. 2007;62:1331-1334. (Pubitemid 47537496)
22. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc. 2006;27: 214-223. (Pubitemid 44153867)
23. Kim K, Sussman G, Hébert J, Lumry William, Lutsky B, Gates D. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96:460-465.
24. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol. 2006;96:363-368. (Pubitemid 43277178)
25. Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Desloratadine Urticaria Study Group. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomised, placebo-controlled trial. J Am Acad Dermatol. 2003;48:535-541. (Pubitemid 36397016)
26. Simons FER, Prenner BM, Finn A, Jr. Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003;111:617- 622. (Pubitemid 36337887)
27. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Desloratadine Study Group. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Int J Dermatol. 2001;40:72-76. (Pubitemid 32201239)
28. Aerius Summary of Product Characteristics. Brussels, Belgium: SP Europe. 2007.
29. Clarinex® (desloratadine) product information. Kenilworth, NJ: Schering- Plough; 2007.
30. Bakker RA, Schoonus SB, Smit MJ, Timmerman H, Leurs R. Histamine H(1)-receptor activation of nuclear factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol. 2001;60:1133-1142. (Pubitemid 33027449)
31. Greasley PJ, Clapham JC. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur J Pharmacol. 2006;553:1-9. (Pubitemid 44794497)
32. National Center for Biomedical Information. [Entrez Gene Website.] NFKB1: nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [[Homo sapiens]]. Available at: http://www.ncbi.nlm.nih.gov/sites/entrez?Db- gene&Cmd-ShowDetailView&TermToSearch-4790&ordinalpos-6&itool- EntrezSystem2.PEntrez.Gene.Gene-ResultsPanel.Gene-RVDocSum Accessed July 11, 2010.
33. Costa T, Cotecchia S. Historical review: negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol Sci. 2005;26:618-624. (Pubitemid 41636306)
34. de Ligt RA, Kourounakis AP, IJzerman AP. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol. 2000;130:1-12. (Pubitemid 30248419)
35. 1 receptor antagonists. Eur J Pharmacol. 2000;387:R5-R7. (Pubitemid 30035384)
36. 1 receptor. Eur J Pharmacol. 2002;449:229 -237.
37. 1receptor. Int Arch Allergy Immunol. 2004;135:313-318. (Pubitemid 40082196)
38. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006; 24:147-174.
39. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111(Suppl):S460 -S475.
40. Lebel B, Bousquet J, Czarlewski W, Campbell AM. Loratadine (L) reduces RANTES release by an epithelial cell line. J Allergy Clin Immunol. 1997;99:S444. Abstract 1802.
41. Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, DuBuske L. Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy. 2005;60:80-85.
42. Di Sciascio MB, Vianale G, Verna N, Petrarca C, Perrone A, et al. Eosinophil recruiting chemokines are down-regulated in peripheral blood mononuclear cells of allergic patients treated with deflazacort or desloratadine. Int J Immunopathol Pharmacol. 2007;20:745-751.
43. Cyr MM, Hayes LM, Crawford L, Baatjes AJ, Keith PK, Denburg JA. The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. Int Arch Allergy Immunol. 2005;138:209 -216. (Pubitemid 41540679)
44. Mullol J, Roca-Ferrer J, Alobid I, Pujols L, Valero A, et al. Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival. Clin Exp Allergy. 2006; 36:52-58.
45. Wang YH, Taché Y, Harris AG, Kreutner W, Daly AF, Wei JY. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy. 2005;60:117-124.
46. Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcεRI〈 cells. Clin Exp Allergy. 1997;27:559 -567. (Pubitemid 27241655)
47. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol. 1995;4(part 2):272-276.
48. Weller K, Maurer M. Desloratadine inhibits human skin mast cell activation and histamine release. J Invest Dermatol. 2009;129:2723- 2726.
49. Tworek D, Bochenska-Marciniak M, Kupczyk M, Górski P, Kuna P. The effect of 4 weeks treatment with desloratadine (5 mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. Pulm Pharmacol Ther. 2006;20:244- 249. (Pubitemid 46240950)
50. Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy. 2001;31:1369 -1377. (Pubitemid 32823873)
51. Zhao Y, Leung PC, Woo KS, Chen GG, Wong YO, Liu SX, van Hasselt CA. Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1). Inflamm Res. 2004;53:664-669. (Pubitemid 40174542)
52. Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel A-B. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamineinduced activation of endothelial cells. Clin Exp Allergy. 1997;27:1167- 1174. (Pubitemid 27448953)
53. Vignola AM, Crampette L, Mondain M, Sauvère G, Czarlewski W, Bousquet J, Campbell AM. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy. 1995;50:200 -203.
54. Traidl-Hoffmann C, Münster I, Ring J, Behrendt H. Impact of desloratadine and loratadine on the crosstalk between human keratinocytes and leukocytes: implications for anti-inflammatory activity of antihistamines. Int Arch Allergy Immunol. 2006;140:315-320. (Pubitemid 44114476)
55. DuBuske L. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8:271-283.
56. DuBuske LM. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders. Expert Opin Pharmacother. 2005;6:2511-2523. (Pubitemid 41701053)
57. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs. 2001;10:547-560. (Pubitemid 32192819)
58. Ciprandi G, Cirillo I. Rupatadine improves nasal symptoms, airflow and inflammation in patients with persistent allergic rhinitis: a pilot study. J Biol Regul Homeost Agents. 2010;24:177-183.
59. Ciprandi G, Cirillo I, Mora F, La Rosa M. Ebastine improves nasal symptoms and airflow and affects response to decongestion test in patients with persistent allergic rhinitis: a pilot study. Allergy Asthma Proc. 2007;28:578 -581.
60. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, et al. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005;5:1800 -1808. (Pubitemid 41586220)
61. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca MA. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. Eur Ann Allergy Clin Immunol. 2005;37:25-29. (Pubitemid 40223286)
62. Gillard M, Strolin Benedetti M, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1- antihistamines. Inflamm Res. 2005;54:367-369.